<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): May 20, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>POLYMEDIX, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Delaware
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>000-51895
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>27-0125925</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>170 N. Radnor Chester Road,<BR>
Suite 300 <BR>Radnor, Pennsylvania
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>&nbsp;<BR>
<BR>19087</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(448) 598-2400 </B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Not Applicable </B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --> </DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1.01. Entry Into a Material Definitive Agreement.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On May&nbsp;20, 2009, PolyMedix, Inc., a Delaware corporation (the &#147;Company&#148;), entered into an
Investment Agreement (&#147;Investment Agreement&#148;) with Dutchess Equity Fund, L.P. (the &#147;Investor&#148;).
Pursuant to the Investment Agreement, the Investor committed to purchase up to $10,000,000 of the
Company&#146;s common stock, over the course of thirty-six months (the &#147;Equity Line Financing&#148;). The
Company may draw on the facility from time to time, as and when it determines appropriate in
accordance with the terms and conditions of the Investment Agreement. The maximum amount that the
Company is entitled to put in any one notice (&#147;Put&#148;) is the greater of (i)&nbsp;200% of the average
daily volume (U.S. market only) of the common stock for the three (3)&nbsp;trading days prior to the
date of delivery of the applicable put notice, multiplied by the average of the closing prices for
such trading days or (ii) $250,000. The purchase price shall be set at ninety-five percent (95%)
of the volume weighted average price (VWAP)&nbsp;of the Company&#146;s common stock during the five (5)
consecutive trading day period beginning on the trading day immediately following the date of
delivery of the applicable put notice; provided, that any trading day during which the daily VWAP
is 10% above or 10% below the VWAP for the entire period will be omitted from the calculation. In
each put notice, the Company will set its minimum acceptable per share price for each put. There
are put restrictions applied on days between the put notice date and the closing date with respect
to that particular Put. During this time, the Company shall not be entitled to deliver another put
notice. The aggregate number of shares issuable by the Company and purchasable by the Investor
under the Investment Agreement is 12,000,000. In addition, the Investor will not be obligated to
purchase shares if the Investor&#146;s total number of shares beneficially held would exceed 4.99% of
the number of shares of the Company&#146;s common stock as determined in accordance with Rule&nbsp;13d-1 of
the Securities Exchange Act of 1934, as amended. In addition, the Company is not permitted to draw
on the facility unless there is an effective registration statement (as further explained below) to
cover the resale of the shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Investment Agreement further provides that each of Dutchess and the Company is entitled to
customary indemnification from the other for any losses or liabilities it suffers as a result of
any breach by the other any provisions of the Investment Agreement or Registration Rights Agreement
(as defined below), or as a result of any lawsuit brought by a third-party arising out of or
resulting from the other party&#146;s execution, delivery, performance or enforcement of the Investment
Agreement or the Registration Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Investment Agreement also contains representations and warranties of each of the Company
and the Investor. The assertions embodied in those representations and warranties were made for
purposes of the Investment Agreement and are subject to qualifications and limitations agreed to by
the respective parties in connection with negotiating the terms of the Investment Agreement. In
addition, certain representations and warranties were made as of a specific date, may be subject to
a contractual standard of materiality different from what a stockholder or investor might view as
material, or may have been used for purposes of allocating risk between the respective parties
rather than establishing matters as facts. Investors should read the Investment Agreement together
with the other information concerning the Company that the Company publicly files in reports and
statements with the Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the terms of a Registration Rights Agreement (&#147;Registration Rights Agreement&#148;)
dated May&nbsp;20, 2009 between the Company and the Investor, the Company is obligated to file a
registration statement with the Securities and Exchange Commission (&#147;SEC&#148;) to register the resale
by the Investor of 12,000,000 shares of the common stock underlying the Investment Agreement within
21&nbsp;days after the closing date. In addition, the Company is obligated to use all commercially
reasonable efforts to have the registration statement declared effective by the SEC within 90&nbsp;days
after the closing date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the preparation of the Investment Agreement and the Registration Rights
Agreement, the Company paid Dutchess a document preparation fee in the amount of $10,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The foregoing description of each of the Investment Agreement and the Registration Rights
Agreement qualified in its entirety by reference to the full text of the Investment Agreement and
the Registration Rights Agreement, respectively, which are filed as Exhibits 10.1 and 10.2 to this
Current Report on Form 8-K and incorporated herein by reference.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;8.01. Other Events.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On May&nbsp;20, 2009, the Company issued a press release (&#147;Press Release&#148;) related to its agreement
with the Investor. A copy of the press release is furnished as Exhibit&nbsp;99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This report contains forward-looking statements within the meaning of Section&nbsp;27A of the
Securities Act, Section&nbsp;21E of the Securities Exchange Act of 1934, as amended and the Private
Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. You should
not place undue reliance on those statements because they are subject to uncertainties and factors
relating to our operations and business environment, all of which are difficult to predict and many
of which are beyond our control. Forward-looking statements include statements regarding our plans,
objectives, goals, strategies, future events, capital expenditures, future results, our competitive
strengths, our business strategy our industry trends and other statements regarding matters that
are not historical facts. These statements often include words such as &#147;may,&#148; &#147;believe,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;estimate,&#148; &#147;goal,&#148; &#147;suggest,&#148; &#147;potential&#148; or similar expressions.
These statements are based on assumptions that we have made in light of our industry experience as
well as our perceptions of historical trends, current conditions, expected future developments and
other factors we believe are appropriate under the circumstances. As you read and consider this
report, you should understand that these statements are not guarantees of performance or results.
They involve risks, uncertainties and assumptions. Although we believe that these forward-looking
statements are based on reasonable assumptions, you should be aware that many factors could affect
our actual financial results or results of operations and could cause actual results to differ
materially from those in the forward-looking statements. A more complete description of these
risks, uncertainties and assumptions is included in the Company&#146;s filings with the Securities and
Exchange Commission. The Company undertakes no obligation to release publicly the results of any
revisions to any such forward-looking statements that may be made to reflect events or
circumstances after the date of this report or to reflect the occurrence of unanticipated events,
except as required by applicable law or regulation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(d)&nbsp;Exhibits
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Investment Agreement by and between PolyMedix, Inc. and Dutchess Equity Fund, LP
dated May&nbsp;20, 2009</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Registration Rights Agreement by and between PolyMedix, Inc. and Dutchess Equity
Fund, LP dated May&nbsp;20, 2009</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press release dated May&nbsp;20, 2009</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">POLYMEDIX, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">May 22, 2009&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Edward F. Smith
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Edward F. Smith&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left" nowrap>Vice President, Finance and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;Index</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Investment Agreement by and between PolyMedix, Inc. and Dutchess Equity Fund, LP
dated May&nbsp;20, 2009</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Registration Rights Agreement by and between PolyMedix, Inc. and Dutchess Equity
Fund, LP dated May&nbsp;20, 2009</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Press release dated May&nbsp;20, 2009</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c86018e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 21217}]
{"company-data": {"conformed-name": "POLYMEDIX INC", "cik": "0001341843", "assigned-sic": "2834", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51895", "film-number": "09847281"}, "business-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104", "phone": "2159666199"}, "mail-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104"}, "former-company": {"former-conformed-name": "BTHC II ACQUISITION CORP", "date-changed": "20051019"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2009
POLYMEDIX, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-51895
27-0125925
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
170 N. Radnor Chester Road,
Suite 300
Radnor, Pennsylvania
19087
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(448) 598-2400
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry Into a Material Definitive Agreement.
On May 20, 2009, PolyMedix, Inc., a Delaware corporation (the "Company"), entered into an
Investment Agreement ("Investment Agreement") with Dutchess Equity Fund, L.P. (the "Investor").
Pursuant to the Investment Agreement, the Investor committed to purchase up to $10,000,000 of the
Company's common stock, over the course of thirty-six months (the "Equity Line Financing"). The
Company may draw on the facility from time to time, as and when it determines appropriate in
accordance with the terms and conditions of the Investment Agreement. The maximum amount that the
Company is entitled to put in any one notice ("Put") is the greater of (i) 200% of the average
daily volume (U.S. market only) of the common stock for the three (3) trading days prior to the
date of delivery of the applicable put notice, multiplied by the average of the closing prices for
such trading days or (ii) $250,000. The purchase price shall be set at ninety-five percent (95%)
of the volume weighted average price (VWAP) of the Company's common stock during the five (5)
consecutive trading day period beginning on the trading day immediately following the date of
delivery of the applicable put notice; provided, that any trading day during which the daily VWAP
is 10% above or 10% below the VWAP for the entire period will be omitted from the calculation. In
each put notice, the Company will set its minimum acceptable per share price for each put. There
are put restrictions applied on days between the put notice date and the closing date with respect
to that particular Put. During this time, the Company shall not be entitled to deliver another put
notice. The aggregate number of shares issuable by the Company and purchasable by the Investor
under the Investment Agreement is 12,000,000. In addition, the Investor will not be obligated to
purchase shares if the Investor's total number of shares beneficially held would exceed 4.99% of
the number of shares of the Company's common stock as determined in accordance with Rule 13d-1 of
the Securities Exchange Act of 1934, as amended. In addition, the Company is not permitted to draw
on the facility unless there is an effective registration statement (as further explained below) to
cover the resale of the shares.
The Investment Agreement further provides that each of Dutchess and the Company is entitled to
customary indemnification from the other for any losses or liabilities it suffers as a result of
any breach by the other any provisions of the Investment Agreement or Registration Rights Agreement
(as defined below), or as a result of any lawsuit brought by a third-party arising out of or
resulting from the other party's execution, delivery, performance or enforcement of the Investment
Agreement or the Registration Rights Agreement.
The Investment Agreement also contains representations and warranties of each of the Company
and the Investor. The assertions embodied in those representations and warranties were made for
purposes of the Investment Agreement and are subject to qualifications and limitations agreed to by
the respective parties in connection with negotiating the terms of the Investment Agreement. In
addition, certain representations and warranties were made as of a specific date, may be subject to
a contractual standard of materiality different from what a stockholder or investor might view as
material, or may have been used for purposes of allocating risk between the respective parties
rather than establishing matters as facts. Investors should read the Investment Agreement together
with the other information concerning the Company that the Company publicly files in reports and
statements with the Securities and Exchange Commission.
Pursuant to the terms of a Registration Rights Agreement ("Registration Rights Agreement")
dated May 20, 2009 between the Company and the Investor, the Company is obligated to file a
registration statement with the Securities and Exchange Commission ("SEC") to register the resale
by the Investor of 12,000,000 shares of the common stock underlying the Investment Agreement within
21 days after the closing date. In addition, the Company is obligated to use all commercially
reasonable efforts to have the registration statement declared effective by the SEC within 90 days
after the closing date.
In connection with the preparation of the Investment Agreement and the Registration Rights
Agreement, the Company paid Dutchess a document preparation fee in the amount of $10,000.
The foregoing description of each of the Investment Agreement and the Registration Rights
Agreement qualified in its entirety by reference to the full text of the Investment Agreement and
the Registration Rights Agreement, respectively, which are filed as Exhibits 10.1 and 10.2 to this
Current Report on Form 8-K and incorporated herein by reference.
Item 8.01. Other Events.
On May 20, 2009, the Company issued a press release ("Press Release") related to its agreement
with the Investor. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
This report contains forward-looking statements within the meaning of Section 27A of the
Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended and the Private
Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. You should
not place undue reliance on those statements because they are subject to uncertainties and factors
relating to our operations and business environment, all of which are difficult to predict and many
of which are beyond our control. Forward-looking statements include statements regarding our plans,
objectives, goals, strategies, future events, capital expenditures, future results, our competitive
strengths, our business strategy our industry trends and other statements regarding matters that
are not historical facts. These statements often include words such as "may," "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "goal," "suggest," "potential" or similar expressions.
These statements are based on assumptions that we have made in light of our industry experience as
well as our perceptions of historical trends, current conditions, expected future developments and
other factors we believe are appropriate under the circumstances. As you read and consider this
report, you should understand that these statements are not guarantees of performance or results.
They involve risks, uncertainties and assumptions. Although we believe that these forward-looking
statements are based on reasonable assumptions, you should be aware that many factors could affect
our actual financial results or results of operations and could cause actual results to differ
materially from those in the forward-looking statements. A more complete description of these
risks, uncertainties and assumptions is included in the Company's filings with the Securities and
Exchange Commission. The Company undertakes no obligation to release publicly the results of any
revisions to any such forward-looking statements that may be made to reflect events or
circumstances after the date of this report or to reflect the occurrence of unanticipated events,
except as required by applicable law or regulation.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
10.1
Investment Agreement by and between PolyMedix, Inc. and Dutchess Equity Fund, LP
dated May 20, 2009
10.2
Registration Rights Agreement by and between PolyMedix, Inc. and Dutchess Equity
Fund, LP dated May 20, 2009
99.1
Press release dated May 20, 2009
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
POLYMEDIX, INC.
May 22, 2009
/s/ Edward F. Smith
Edward F. Smith
Vice President, Finance and Chief Financial Officer
Exhibit Index
Exhibit No.
10.1
Investment Agreement by and between PolyMedix, Inc. and Dutchess Equity Fund, LP
dated May 20, 2009
10.2
Registration Rights Agreement by and between PolyMedix, Inc. and Dutchess Equity
Fund, LP dated May 20, 2009
99.1
Press release dated May 20, 2009